产品
编 号：F188289
分子式：C12H7FN2OS
分子量：246.26
分子式：C12H7FN2OS
分子量：246.26
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 158093-65-3
产品详情
生物活性：
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC50s of 8.39, 9.74, 2.49 and 5.35 μM, respectively.
体内研究：
PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition.Animal Model:Male NMRI:nu/nu mice (Neuroblastoma xenografts)
Dosage:25 mg/kg
Administration:Intraperitoneally (PU139) with Dxorubicin at 8?mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1?h.
Result:Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings.
体外研究：
PU139 inhibits cell growth with GI50s of PU139 相关抗体:
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC50s of 8.39, 9.74, 2.49 and 5.35 μM, respectively.
体内研究：
PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition.Animal Model:Male NMRI:nu/nu mice (Neuroblastoma xenografts)
Dosage:25 mg/kg
Administration:Intraperitoneally (PU139) with Dxorubicin at 8?mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1?h.
Result:Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings.
体外研究：
PU139 inhibits cell growth with GI50s of PU139 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备